Jonathan P Smith1, Neel R Gandhi1,2, N Sarita Shah1,3, Koleka Mlisana4,5, Pravi Moodley4,5, Brent A Johnson6, Salim Allana1, Angela Campbell1, Kristin N Nelson1, Iqbal Master7, James C M Brust8. 1. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA. 2. Emory School of Medicine, Emory University, Atlanta, GA. 3. Division of Global HIV and Tuberculosis, US Centers for Disease Control and Prevention, Atlanta, GA. 4. University of KwaZulu-Natal, Durban, South Africa. 5. National Health Laboratory Services, Durban, South Africa. 6. University of Rochester, Rochester, NY. 7. King Dinuzulu Hospital, Durban, South Africa; and. 8. Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY.
Abstract
BACKGROUND: South Africa has among the highest incidence of multidrug-resistant tuberculosis (MDR-TB) and more than 70% of patients are HIV co-infected. MDR-TB treatment is associated with frequent adverse events (AEs). Although guidelines recommend concurrent treatment of MDR-TB and HIV, safety data on concurrent therapy are limited. METHODS: We conducted a prospective observational study of MDR-TB patients with and without HIV-coinfection in South Africa between 2011 and 2015. Participants received standardized MDR-TB and HIV regimens. Participants were followed monthly for the duration of MDR-TB therapy and screened for clinical and laboratory AEs. Audiometry was performed monthly during the intensive phase; color discrimination testing was performed every 2 months. RESULTS: We enrolled 150 HIV-infected and 56 HIV-uninfected participants. Nearly all experienced at least one clinical (93%) or laboratory (96%) AE. The most common clinical AEs were peripheral neuropathy (50%) and difficulty sleeping (48%); the most common laboratory AEs were hypokalemia (47%) and decreased creatinine clearance (46%). Among 19 clinical and lab AEs examined, there were no differences by HIV status, except for diarrhea (27% HIV-infected vs. 13% HIV-uninfected, P = 0.03). Hearing loss was experienced by 72% of participants (8% severe loss). Fourteen percent experienced color discrimination loss (4% severe loss). There were no differences in frequency or severity of hearing or vision loss by HIV status. CONCLUSIONS: AEs were common, but not more frequent or severe among MDR-TB/HIV co-infected participants receiving concurrent antiretroviral therapy. Given the favorable treatment outcomes associated with concurrent treatment, antiretroviral therapy initiation should not be delayed in MDR-TB patients with HIV-coinfection.
BACKGROUND: South Africa has among the highest incidence of multidrug-resistant tuberculosis (MDR-TB) and more than 70% of patients are HIV co-infected. MDR-TB treatment is associated with frequent adverse events (AEs). Although guidelines recommend concurrent treatment of MDR-TB and HIV, safety data on concurrent therapy are limited. METHODS: We conducted a prospective observational study of MDR-TB patients with and without HIV-coinfection in South Africa between 2011 and 2015. Participants received standardized MDR-TB and HIV regimens. Participants were followed monthly for the duration of MDR-TB therapy and screened for clinical and laboratory AEs. Audiometry was performed monthly during the intensive phase; color discrimination testing was performed every 2 months. RESULTS: We enrolled 150 HIV-infected and 56 HIV-uninfected participants. Nearly all experienced at least one clinical (93%) or laboratory (96%) AE. The most common clinical AEs were peripheral neuropathy (50%) and difficulty sleeping (48%); the most common laboratory AEs were hypokalemia (47%) and decreased creatinine clearance (46%). Among 19 clinical and lab AEs examined, there were no differences by HIV status, except for diarrhea (27% HIV-infected vs. 13% HIV-uninfected, P = 0.03). Hearing loss was experienced by 72% of participants (8% severe loss). Fourteen percent experienced color discrimination loss (4% severe loss). There were no differences in frequency or severity of hearing or vision loss by HIV status. CONCLUSIONS: AEs were common, but not more frequent or severe among MDR-TB/HIV co-infected participants receiving concurrent antiretroviral therapy. Given the favorable treatment outcomes associated with concurrent treatment, antiretroviral therapy initiation should not be delayed in MDR-TB patients with HIV-coinfection.
Authors: E Nathanson; R Gupta; P Huamani; V Leimane; A D Pasechnikov; T E Tupasi; K Vink; E Jaramillo; M A Espinal Journal: Int J Tuberc Lung Dis Date: 2004-11 Impact factor: 2.373
Authors: James A Seddon; Peter Godfrey-Faussett; Kayleen Jacobs; Adam Ebrahim; Anneke C Hesseling; H Simon Schaaf Journal: Eur Respir J Date: 2012-06-14 Impact factor: 16.671
Authors: A Reuter; P Tisile; D von Delft; H Cox; V Cox; L Ditiu; A Garcia-Prats; S Koenig; E Lessem; R Nathavitharana; J A Seddon; J Stillo; A von Delft; J Furin Journal: Int J Tuberc Lung Dis Date: 2017-11-01 Impact factor: 2.373
Authors: Karen Shean; Elizabeth Streicher; Elize Pieterson; Greg Symons; Richard van Zyl Smit; Grant Theron; Rannakoe Lehloenya; Xavier Padanilam; Paul Wilcox; Tommie C Victor; Paul van Helden; Martin P Grobusch; Martin Groubusch; Robin Warren; Motasim Badri; Keertan Dheda Journal: PLoS One Date: 2013-05-07 Impact factor: 3.240
Authors: Gilbert Lazarus; Kevin Tjoa; Anthony William Brian Iskandar; Melva Louisa; Evans L Sagwa; Nesri Padayatchi; Vivian Soetikno Journal: PLoS One Date: 2021-03-04 Impact factor: 3.240